RESUMEN
Infliximab is a chimeric monoclonal antibody, which specifically binds to tumor necrosis factor (TNF-alpha) and blocks its activity. Based on previous evidence that TNF-alpha has been involved in the pathogenesis of psoriasis, multiple controlled trials have shown that infliximab has provided a high degree of clinical benefit in the treatment of psoriasis and psoriatic arthritis allowing a major and rapid improvement in these patients. We review several clinical trials, which have firmly established both efficacy and safety of Infliximab in the treatment of moderate to severe psoriasis and psoriatic arthritis.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/efectos adversos , Ensayos Clínicos Controlados como Asunto , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Infliximab , Masculino , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Tiempo , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
Infliximab es un anticuerpo quimérico monoclonal que se une específicamente al factor de necrosistumoral alfa (TNF-α) y bloquea su actividad. Múltiples ensayos clínicos, basándose en evidencias previas relacionadascon el papel del TNF-α en la patogénesis de la psoriasis, han demostrado que infliximab consigue un alto grado de beneficio clínico en el tratamiento de la psoriasis y artritis psoriásica, permitiendo alcanzar una mejoría importante y rápida en estos pacientes. Revisamos diferentes ensayos clínicos que demuestran la eficacia y la seguridad de infliximab en el tratamiento de psoriasis moderada a severa y artritis psoriásica (AU)
Infliximab is a chimeric monoclonal antibody, which specifically binds to tumor necrosis factor (TNF-α) and blocks its activity. Based on previous evidence that TNF-αhas been involved in the pathogenesis of psoriasis, multiple controlled trials have shown that infliximab has provided a high degree of clinical benefit in the treatment of psoriasis and psoriatic arthritis allowing a major and rapid improvement in these patients.We review several clinical trials, which have firmly established both efficacy and safety of Infliximab in the treatment of moderate to severe psoriasis and psoriatic arthritis (AU)